| Literature DB >> 9893619 |
L Iyer1, M J Ratain.
Abstract
Cancer chemotherapy is limited by significant inter-individual variations in responses and toxicities. Such variations are often due to genetic alterations in drug metabolising enzymes (pharmacokinetic polymorphisms) or receptor expression (pharmacodynamic polymorphisms). Pharmacogenetic screening prior to anticancer drug administration may lead to identification of specific populations predisposed to drug toxicity or poor drug responses. The role of polymorphisms in specific enzymes, such as thiopurine S-methyltransferases (TPMT), dihydropyrimidine dehydrogenase (DPD), aldehyde dehydrogenases (ALDH), glutathione S-transferases (GST), uridine diphosphate glucuronosyl-transferases (UGTs) and cytochrome P450 (CYP 450) enzymes in cancer therapy are discussed in this review.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9893619 DOI： 10.1016/s0959-8049(98)00230-5
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162